Compass Therapeutics, Inc. Common Stock
CMPXCompass Therapeutics, Inc. is a biotechnology company focused on developing innovative immunotherapies for cancer and other diseases. The company utilizes proprietary platform technologies to discover and develop monoclonal antibodies and other biologics aimed at modulating the immune system to combat chronic diseases.
Company News
Compass Therapeutics announced that its abstract for tovecimig, a DLL4 x VEGF-A bispecific antibody, has been accepted for an oral presentation at the ESMO Congress 2026 in Madrid. The presentation will showcase Phase 2/3 COMPANION-002 trial results evaluating tovecimig combined with paclitaxel in patients with advanced biliary tract cancer, to b...
Compass Therapeutics announced Phase 1 clinical data for CTX-8371, a novel PD-1×PD-L1 bispecific antibody, showing promising monotherapy activity in patients with advanced malignancies resistant to prior checkpoint inhibitors. The drug demonstrated deep and durable responses in triple-negative breast cancer, Hodgkin lymphoma, and non-small cell ...
Johnson Fistel, PLLP is investigating potential securities law violations by Compass Therapeutics following the disclosure that its lead drug candidate tovecimig failed to meet the overall survival secondary endpoint in the COMPANION-002 clinical trial. The company reported median overall survival of 8.9 months versus 9.4 months for the control a...
Compass Therapeutics will host a webcast on April 27, 2026 to present topline secondary endpoints from its Phase 2/3 COMPANION-002 study evaluating tovecimig, a DLL4 x VEGF-A bispecific antibody combined with paclitaxel, in patients with advanced biliary tract cancer. The study has reached its prespecified event threshold of 80% overall survival ...
Compass Therapeutics announced participation in two healthcare investor conferences in December 2025, highlighting their ongoing clinical-stage oncology research focused on antibody-based therapeutics targeting tumor growth and immune system interactions.
